We are live on ! Find out more
BCM

Boone Capital Management Portfolio holdings

AUM $326M
1-Year Est. Return 86.31%
This Fund
S&P 500
This Quarter Est. Return
+12.96%
1 Year Est. Return
+86.31%
3 Year Est. Return
+255.12%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$386M
AUM Growth
+$2.38M
Cap. Flow
-$39.3M
Cap. Flow %
-10.18%
Top 10 Hldgs %
75.9%
Holding
21
New
2
Increased
6
Reduced
8
Closed
4

Top Buys

Rank Stock Value
1
CHE icon
Chemed
CHE
+$22.3M
2
PRGO icon
Perrigo
PRGO
+$12.5M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$4.16M
4
OFIX icon
Orthofix Medical
OFIX
+$2.49M
5
UNM icon
Unum
UNM
+$1.83M

Top Sells

Rank Stock Value
1
DHR icon
Danaher
DHR
+$11.9M
2
BAX icon
Baxter International
BAX
+$10.3M
3
CRL icon
Charles River Laboratories
CRL
+$9.98M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$9.77M
5
HCSG icon
Healthcare Services Group
HCSG
+$9.24M

Sector Composition

Rank Sector Weight
1 Healthcare 80.83%
2 Financials 14.86%
3 Materials 4.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNM icon
1
Unum
UNM
$13.7B
$57.3M 14.86%
964,170
+33,625
+4% +$1.83M
GMED icon
2
Globus Medical
GMED
$10.7B
$46.6M 12.09%
651,710
+14,395
+2% +$1.02M
CI icon
3
Cigna
CI
$75.1B
$45.7M 11.85%
131,926
– –
MOH icon
4
Molina Healthcare
MOH
$10.2B
$24.7M 6.4%
71,704
-27,390
-28% -$9.04M
CHE icon
5
Chemed
CHE
$7.06B
$23.7M 6.14%
+39,422
New +$22.3M
PNTG icon
6
Pennant Group
PNTG
$1.4B
$22.9M 5.93%
641,255
-58,711
-8% -$1.8M
MIRM icon
7
Mirum Pharmaceuticals
MIRM
$6.55B
$21.2M 5.5%
543,843
+20,164
+4% +$804K
DHR icon
8
Danaher
DHR
$137B
$17.1M 4.42%
61,327
-45,033
-42% -$11.9M
IDYA icon
9
IDEAYA Biosciences
IDYA
$3.43B
$16.8M 4.37%
531,630
+109,581
+26% +$4.16M
BAX icon
10
Baxter International
BAX
$13.5B
$16.8M 4.35%
441,821
-279,457
-39% -$10.3M
BERY
11
DELISTED
Berry Global Group, Inc.
BERY
$16.7M 4.32%
266,785
-16,039
-6% -$953K
IQV icon
12
IQVIA
IQV
$38.3B
$16M 4.15%
67,582
-27,152
-29% -$6.41M
AMPH icon
13
Amphastar Pharmaceuticals
AMPH
$868M
$15.4M 3.98%
316,556
-178,533
-36% -$7.83M
OFIX icon
14
Orthofix Medical
OFIX
$467M
$14.5M 3.77%
930,507
+155,139
+20% +$2.49M
VKTX icon
15
Viking Therapeutics
VKTX
$3.72B
$12.2M 3.17%
192,889
+18,123
+10% +$1.06M
PRGO icon
16
Perrigo
PRGO
$1.41B
$11.9M 3.07%
+452,221
New +$12.5M
CERT icon
17
Certara
CERT
$1.23B
$6.34M 1.64%
541,830
-177,153
-25% -$2.34M
CRL icon
18
Charles River Laboratories
CRL
$11.1B
– –
-48,288
Closed -$9.98M
HCSG icon
19
Healthcare Services Group
HCSG
$1.57B
– –
-873,018
Closed -$9.24M
TARS icon
20
Tarsus Pharmaceuticals
TARS
$2.53B
– –
-216,047
Closed -$5.87M
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.07B
– –
-250,460
Closed -$9.77M

Similar funds

ISFAN
Investor's Fiduciary Advisor Network Snoqualmie, Washington $326M AUM 19.7% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
AFA
Alpha Financial Advisors Charlotte, North Carolina $326M AUM 15.49% 1-Year Est. Return
ECH
ER Collective Holdings Washington, District of Columbia $326M AUM
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
MVM
Menlo Ventures Management Menlo Park, California $327M AUM
CCG
Ceeto Capital Group Coral Gables, Florida $326M AUM 24.81% 1-Year Est. Return
TC
TFR Capital Plano, Texas $326M AUM 24.24% 1-Year Est. Return

Boone Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Boone Capital Management held 21 positions worth $386M, up 0.62% from $383M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Boone Capital Management withdrew a net $39.3M in Q3 2024, closing 4 positions and reducing 8 holdings. Its most notable exit was Charles River Laboratories, an estimated $9.98M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 84% a quarter earlier, followed by Financials and Materials.

Against the trend, Boone Capital Management opened a new position in Chemed worth $23.7M.

  • Boone Capital Management's largest Q3 2024 buy was Chemed: 39,422 shares worth $23.7M.
  • Boone Capital Management added most to IDEAYA Biosciences in Q3 2024, an estimated $4.16M increase.
  • Boone Capital Management's biggest Q3 2024 reduction was Danaher, cutting an estimated $11.9M.
  • Boone Capital Management fully exited Charles River Laboratories in Q3 2024, selling an estimated $9.98M.
  • Boone Capital Management's ten largest holdings make up 76% of its $386M portfolio in Q3 2024.
  • Boone Capital Management opened 2 new positions and closed 4 in Q3 2024.
  • Boone Capital Management's portfolio value rose 0.62% quarter-over-quarter to $386M.

Based on Boone Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.